Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Atractylenolide-Ⅲ binds non-structural protein-1 to suppress influenza A by modulating macrophage polarization and alternative polyadenylation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Jinlong, Guo Huiyi, Yang Yan, Liang Guorun, Chen Zhixuan, Li Dan, Liang Hao, Qiu Jiayin, Mei Qinghua, Liu Shuwen, Yang Jie, Wu Wenjiao
Аннотация
BACKGROUND: Drug-resistant influenza demands novel antiviral treatments. Non-structural protein 1 (NS1) of influenza A virus (IAV) regulates the viral life cycle and host immune response, thus becoming a promising therapeutic target. The atractylenolide (ACT) -Ⅲ exhibits notable anti-IAV efficacy; however, its in vivo anti-IAV activity and the underlying mechanisms need further exploration.
PURPOSE: We explored the binding affinity of ACT-Ⅲ with NS1 and elucidated the in vivo anti-influenza activity and underlying mechanism of ACT-Ⅲ.
STUDY DESIGN AND METHODS: Surface plasmon resonance (SPR) analysis was utilized to determine the binding affinity of ACT-Ⅲ to NS1. The anti-IAV activity of ACT-Ⅲ was further tested in vitro using IAV-infected lung epithelial cells and in vivo in IAV-challenged mice. The evaluation criteria included the assessment of virus-associated cytopathies, viral protein and gene expression, virus titer, mice weight loss, survival curve, and lung pathology. Transcriptomic sequencing was conducted to evaluate the inflammation regulatory function of ACT-Ⅲ in IAV-infected Raw264.7 cells. Quantitative real-time PCR (qRT-PCR) was used to detect the target gene expression. Flow cytometry was utilized to assess macrophages polarization. Co-immunoprecipitation was employed to examine the impact of ACT-Ⅲ on the interaction between NS1 and cleavage and polyadenylation-specific factor 4 (CPSF4).
RESULTS: ACT-Ⅲ exhibited anti-IAV activity in vitro and in vivo, mitigating virus-induced lung injury. Mechanistically, ACT-Ⅲ impeded IAV infection and viral induced inflammation by binding to viral NS1, which reduced the activation of pro-inflammatory signaling, and disrupted the NS1-CPSF4 interaction that mediates alternative polyadenylation (APA).
CONCLUSION: ACT-Ⅲ inhibits IAV replication and viral pneumonia by binding to NS1, showing potential as a therapeutic agent for IAV treatment.
PURPOSE: We explored the binding affinity of ACT-Ⅲ with NS1 and elucidated the in vivo anti-influenza activity and underlying mechanism of ACT-Ⅲ.
STUDY DESIGN AND METHODS: Surface plasmon resonance (SPR) analysis was utilized to determine the binding affinity of ACT-Ⅲ to NS1. The anti-IAV activity of ACT-Ⅲ was further tested in vitro using IAV-infected lung epithelial cells and in vivo in IAV-challenged mice. The evaluation criteria included the assessment of virus-associated cytopathies, viral protein and gene expression, virus titer, mice weight loss, survival curve, and lung pathology. Transcriptomic sequencing was conducted to evaluate the inflammation regulatory function of ACT-Ⅲ in IAV-infected Raw264.7 cells. Quantitative real-time PCR (qRT-PCR) was used to detect the target gene expression. Flow cytometry was utilized to assess macrophages polarization. Co-immunoprecipitation was employed to examine the impact of ACT-Ⅲ on the interaction between NS1 and cleavage and polyadenylation-specific factor 4 (CPSF4).
RESULTS: ACT-Ⅲ exhibited anti-IAV activity in vitro and in vivo, mitigating virus-induced lung injury. Mechanistically, ACT-Ⅲ impeded IAV infection and viral induced inflammation by binding to viral NS1, which reduced the activation of pro-inflammatory signaling, and disrupted the NS1-CPSF4 interaction that mediates alternative polyadenylation (APA).
CONCLUSION: ACT-Ⅲ inhibits IAV replication and viral pneumonia by binding to NS1, showing potential as a therapeutic agent for IAV treatment.